Pharmafile Logo

Voyager Therapeutics

- PMLiVE

Novartis announces delay in UK cholesterol drug study

The delay was caused by recruitment issues during the COVID-19 pandemic

- PMLiVE

Novartis agrees to help produce Roche’s repurposed COVID-19 drug

Novartis will make ingredients for Actemra/RoActemra, which is being investigated in COVID-19

- PMLiVE

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

PD-1 inhibitor improved overall survival compared to chemotherapy medication docetaxel

- PMLiVE

FDA approves new self-injection administration for Xolair

Drug is approved for asthma and other allergic and inflammatory conditions

- PMLiVE

Novartis bolsters radioligand therapy pipeline with new licence agreement

Radioligand therapies are a new potential class of precision oncology drugs

Roche Basel Switzerland

EU authorises Roche’s spinal muscular atrophy treatment Evrysdi

First SMA treatment approved in the EU that can be taken at home

- PMLiVE

Novartis gains EU approval for relapsing MS drug Kesimpta

The drug reduces the number of confirmed relapses in MS patients

- PMLiVE

Positive late-stage results for Novartis’ radioligand therapy in advanced prostate cancer

Therapy hit both primary endpoints of overall survival and radiographic progression-free survival

- PMLiVE

Novartis’ canakinumab misses the mark in previously treated NSCLC

Drug failed to improve survival in previously-treated metastatic NSCLC patients

- PMLiVE

CureVac signs manufacturing agreement with Novartis for COVID-19 vaccine candidate

Novartis will aid manufacturing for up to 50 million doses of CureVac's vaccine in 2021

- PMLiVE

Novartis partners with Bill & Melinda Gates Foundation on ‘accessible’ sickle cell gene therapy

Project will aim to discover and develop a gene therapy for sickle cell disease

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links